Cost-Effectiveness of Multiplexed Predictive Biomarker Screening in Non-Small-Cell Lung Cancer

Abstract

IntroductionPopulation-wide screening for epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) gene rearrangements to inform cancer therapy in non-small-cell lung cancer (NSCLC) is recommended by guidelines. We estimated cost-effectiveness of multiplexed predictive biomarker screening in metastatic NSCLC from a societal perspective in the United States.MethodsWe constructed a microsimulation model to compare the life expectancy and costs of multiplexed testing and molecularly guided therapy versus treatment with cisplatin-pemetrexed (CisPem). All testing interventions included a two-step algorithm of concurrent EGFR mutation and ALK overexpression testing with immunohistochemistry followed by ALK rearrangement confirmation with a fluorescence in situ hybridization assay for immunohistochemistry-positive results. Three strategies were included: “Test-treat” approach, where molecularly guided therapy was initiated after obtainment of test results; “Empiric switch therapy,” with concurrent initiation of CisPem and testing and immediate switch to test-result conditional treatment after one cycle of CisPem; and “Empiric therapy” approach in which CisPem was continued for four cycles before start of a tyrosine kinase inhibitor.ResultsThe incremental cost-effectiveness ratio for “Test-treat” compared with treatment with CisPem was $136,000 per quality-adjusted life year gained. Both empiric treatment approaches had less favorable incremental cost-effectiveness ratios. “Test-treat” and “Empiric switch therapy” yielded higher expected outcomes in terms of quality-adjusted life years and life-years than “Empiric therapy.” These results were robust across plausible ranges of model inputs.ConclusionFrom a societal perspective, our cost-effectiveness results support the value of multiplexed genetic screening and molecularly guided therapy in metastatic NSCLC